Intraparietal sulcus depth is associated with negative symptomatology in patients with first-episode psychosis
The study of brain morphology parameters in patients with first-episode psychosis (FEP) could help detect early brain footprints related to this disease and its predominant symptomatology. We examined gray matter (GM) volume, cortical thickness (CT), gyrification index (GI), and sulcus depth (SD) differences between patients with FEP and healthy control (HC) participants. We also investigated the associations of these brain parameters with symptomatology in FEP. Our sample consisted of 182 participants, 105 patients with FEP and 77 HC. All participants had a brain structural image acquired with a 3T scanner. Symptomatology was assessed with the Positive and Negative Syndrome Scale (PANSS), considering both the original 3-factor structure and an alternative 5-factor structure proposed by Emsley. Patients with FEP showed reduced GM volume than HC in the anterior cingulate gyrus and adjacent regions. We also found that greater SD of the intraparietal sulcus was associated with more severe negative symptomatology in FEP. This association was found with the total score of this subscale and several of its items. Additionally, lower SD and lower CT in the right parietal lobe were associated with a higher Emsley's excited factor score, which includes items related to manic symptoms. Our results suggest that an abnormal depth of the intraparietal sulcus may be an indicator of impaired functioning of this region, which may in turn be associated with social and emotional issues. Overall, SD seems to provide relevant information on the brain morphology of FEP, making it a promising marker for the early stages of psychosis.
Authors
- Clara Serra‐Arumí
- Pablo Andrés-Camazón (ORCID: https://orcid.org/0000-0002-7322-1248)
- Christian Núñez (ORCID: https://orcid.org/0000-0003-4104-6235)
- Christian Stephan‐Otto (ORCID: https://orcid.org/0000-0002-6326-7648)
- Miquel Bernardo (ORCID: https://orcid.org/0000-0001-8748-6717)
- Daniel Bergé (ORCID: https://orcid.org/0000-0003-2544-1016)
- Anabel Martínez‐Arán (ORCID: https://orcid.org/0000-0002-0623-6263)
- Elena de la Serna (ORCID: https://orcid.org/0000-0002-7869-9881)
- Joost Janssen (ORCID: https://orcid.org/0000-0001-7613-2067)
- Gisela Mezquida (ORCID: https://orcid.org/0000-0002-6080-2203)
- Sílvia Amoretti (ORCID: https://orcid.org/0000-0001-6017-2734)
- Anna Butjosa (ORCID: https://orcid.org/0000-0001-5317-9508)
- Manuel J Cuesta
- Judith Usall
Institutions
- Hospital de Sant Pau (ES)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Complejo Hospitalario de Navarra (ES)
- Navarre Institute of Health Research (ES)
- Sant Joan de Déu Research Foundation (ES)
- Biomedical Research Institute (US)
- Fundació Clínic per a la Recerca Biomèdica (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Institut de Recerca Sant Joan de Déu
- Universitat de Barcelona (ES)
Publication Details
- Journal
- European Neuropsychopharmacology
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1016/j.euroneuro.2025.08.004
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00